



Cystic Fibrosis: Genetics, Pathophysiology and Novel Therapeutic Approaches

Guest Editors:

Prof. Dr. Massimo Conese

Department of Clinical and
Experimental Medicine,
University of Foggia, 71122
Foggia, Italy

Dr. Onofrio Laselva

Laboratory of Experimental and
Regenerative Medicine,
Department of Medical and
Surgical Sciences, University of
Foggia, 71122 Foggia, Italy

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

Cystic fibrosis (CF) is a life-threatening autosomal recessive disorder due to mutations in the CF Transmembrane Conductance Regulator (*CFTR*) gene that cause morbidity and mortality mainly by inducing lung disease. This Special Issue is devoted to appraising the most recent developments in CF research and its clinical facets, focusing on the fields of genetics, theranostics, immunology, infections, inflammation, and novel therapeutic approaches. In the coronavirus 2019 (COVID-19) era, the natural history of CF pathophysiology is changing, thereby this Special Issue will be insightful in discussing how the present pandemic infection could determine other clinical features in CF patients. Finally, basic and applied research have sought and identified etiological treatments for CF, highlighted by the clinical use of modulators (potentiators, correctors) of the mutated CFTR protein. Novel genetic and stem cell-based treatments as potential therapeutic approaches to cure CF are at the forefront of CF research and will be also covered in this Special Issue.

